Source-grounded facts extracted from FibroBiologics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Kathleen Rubins was appointed as Class III Director at FibroBiologics, Inc..
“On July 8, 2026, the Board appointed Kathleen Rubins, Ph.D. as a Class III director of the Board, effective July 8, 2026, to serve until the expiration of her term at the 2029 annual meeting of stockholders.”
Matt Link resigned as Director at FibroBiologics, Inc..
“On July 2, 2026, Matt Link notified FibroBiologics, Inc. (the “Company”) that he was resigning from the Board of Directors (the “Board”), effective as of July 2, 2026.”
FibroBiologics, Inc. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC (effective 2026-05-01).
“on May 1, 2026, FibroBiologics, Inc. (the “Company”) entered into that certain At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (the “Sales Agent”)”
FibroBiologics, Inc. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at up to $6,150,000 (effective 2026-05-01).
“On May 1, 2026, FibroBiologics, Inc. (the “Company”) entered into an At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (the “Sales Agent”) under which the Company may issue and sell in a registered offering shares of its common stock, par value $0.00001 per share (the “Common Stock”), having an aggregate offering price of up to $6,150,000”
FibroBiologics, Inc.: Amended Section 2.07 of the Bylaws to reduce the quorum requirement for stockholder meetings from a majority of voting power to one-third of voting power (effective 2026-04-16).
“On April 16, 2026, the board of directors (the “Board”) of FibroBiologics, Inc. (the “Company”) amended and restated the Company’s Amended and Restated Bylaws (the “Bylaws”) to amend Section 2.07 of the Bylaws to change the requirement for quorum at a meeting of the stockholders of the Company from a majority of voting power to one-third of the voting power (the “Amendment”).”
FibroBiologics, Inc. terminated Sublease Buyout Agreement with United Fire & Casualty Co. valued at Single payment of $45,108.25; expected savings of approximately $0.8 million in future rent payments (effective 2026-04-03).
“On April 3, 2026, FibroBiologics, Inc. (the “Company”) entered into a Sublease Buyout Agreement (the “Lease Termination Agreement”) with United Fire & Casualty Co. (doing business as United Fire Group) (the “Sublandlord”) to terminate that certain Sublease Agreement, which was effective as of October 5, 2022 (“Sublease”), pursuant to which Sublandlord subleased to the Company certain premises located at the third floor of 455 E. Medical Center Blvd, Webster, County of Harris, Texas 77598.”
FibroBiologics, Inc. terminated Lease Termination Agreement with United Fire & Casualty Co. (doing business as United Fire Group) valued at $45,108.25 (effective 2026-04-03).
“On April 3, 2026, FibroBiologics, Inc. (the “Company”) entered into a Sublease Buyout Agreement (the “Lease Termination Agreement”) with United Fire & Casualty Co. (doing business as United Fire Group) (the “Sublandlord”) to terminate that certain Sublease Agreement, which was effective as of October 5, 2022 (“Sublease”)”
FibroBiologics, Inc.: Implemented a one-for-twenty reverse stock split of common stock via amendment to the Amended and Restated Certificate of Incorporation (effective 2026-03-30).
“On March 25, 2026, FibroBiologics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware (the “Certificate of Amendment”), which became effective at 12:01 a.m. Eastern Time on March 30, 2026, and implemented a one-for-twenty (1:20) reverse stock split”
FibroBiologics, Inc. entered into Purchase Agreement with certain investors (effective 2026-03-31).
“certain of the investors purchased their Shares and Pre-Funded Warrants, together with the accompanying Warrants, pursuant to a securities purchase agreement, dated March 31, 2026, by and among the Company and such investors (the “Purchase Agreement”).”
FibroBiologics, Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(a)(2), 5550(b)(2)).
“February 3, 2026, the Company received formal notice from the Staff that, based upon the Company’s continued non-compliance with the MVLS Rule, the deficiency serves as an additional basis for the delisting of the Company’s securities from Nasdaq (the “Notice”). The Notice indicated that, in addition to the previously-reported bid price deficiency under Listing Rule 5550(a)(2) (the “Bid Price Rule”), the Nasdaq Hearings Panel (the “Panel”) will consider the Company’s plan to regain compliance with the MVLS Rule in their decision regarding the Company’s request for continued listing on The Nasd”
FibroBiologics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).
“December 30, 2025, the Company received a second notification indicating that the Staff planned to delist the Company’s securities due to the Company’s continued non-compliance with the Rule as of December 29, 2025, unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company plans to timely request a hearing before the Panel, which request will stay any further suspension or delisting action by the Staff at least pending the outcome of the hearing and the expiration of any extension that may be granted to the Company by the Panel. The Company intend”
FibroBiologics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“July 1, 2025, FibroBiologics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the bid price for the Company’s shares of common stock had closed below the minimum threshold of $1.00 per share, as required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Rule”), for the previous 30 consecutive trading day period. In accordance with Listing Rule 5810(c)(3)(A), the Company was provided with a 180-calendar day period to regain compliance with t”
FibroBiologics, Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $1.7 million (effective 2025-12-14).
“On December 14, 2025, FibroBiologics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which (i) the Company agreed to issue and sell to the Purchasers, in a registered direct offering (the “Registered Direct Offering”), 5,227,275 shares (the “Shares”) of the Company’s common stock”
FibroBiologics, Inc. issued warrants to purchase up to 365,909 shares of Common Stock of warrant to H.C. Wainwright & Co., LLC (placement agent) for services as placement agent.
“the Company will issue to the Placement Agent (or its designees) warrants to purchase 7.0% of the number of Shares of Common Stock sold in this the Registered Direct Offering (or warrants to purchase up to 365,909 shares of Common Stock), at an exercise price of $0.4125 per share (the "Placement Agent Warrants").”
FibroBiologics, Inc. issued 5,227,275 shares of Common Stock underlying Warrants of warrant to institutional investors for no additional consideration beyond the Purchase Agreement; exercise price $0.33 per share.
“5,227,275 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”). The price of each Share in the Registered Direct Offering is $0.33 (the “Offering Price”). Additionally, pursuant to the Purchase Agreement, the Company will issue to the Purchasers, in a concurrent private placement, warrants to purchase one”
FibroBiologics, Inc. issued 5,227,275 shares of common stock to institutional investors for gross proceeds to the Company from the offerings are expected to be approximately $1.7 million, before deducting placement agent fees and offering expenses.
“approval as described below. The exercise price of the Warrants is $0.33 per share. The gross proceeds to the Company from the offerings are expected to be approximately $1.7 million, before deducting placement agent fees and offering expenses payable by the Company. In addition, if the holders of the unregistered Warrants exercise such Warrants in full for”
FibroBiologics, Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $1.5 million (effective 2025-11-24).
“On November 24, 2025, FibroBiologics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which (i) the Company agreed to issue and sell to the Purchasers, in a registered direct offering (the “Registered Direct Offering”), 4,477,614 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”).”
FibroBiologics, Inc. issued to purchase up to 313,433 shares of Common Stock of warrant to Placement Agent (H.C. Wainwright & Co., LLC) for issued as compensation; exercise price $0.4188 per share.
“Additionally, the Company will issue to the Placement Agent (or its designees) warrants to purchase 7.0% of the number of Shares of Common Stock sold in this the Registered Direct Offering (or warrants to purchase up to 313,433 shares of Common Stock), at an exercise price of $0.4188 per share (the “Placement Agent Warrants”).”
FibroBiologics, Inc. issued to purchase 4,477,614 shares of Common Stock of warrant to institutional investors (the Purchasers) for exercise price $0.335 per share; no additional consideration at issuance.
“4,477,614 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”). The price of each Share in the Registered Direct Offering is $0.335 (the “Offering Price”). Additionally, pursuant to the Purchase Agreement, the Company will issue and sell to the Purchasers, in a concurrent private placement, warrants to”
FibroBiologics, Inc. issued 12,110,203 shares of warrant to the Purchaser for Not stated separately; warrants issued in connection with the Registered Direct Offering.
“Additionally, pursuant to the Purchase Agreement, the Company will issue and sell to the Purchaser, in a concurrent private placement, warrants to purchase one share of its common stock for each share of common stock or Pre-Funded Warrant purchased in the Registered Direct Offering, for an aggregate of 12,110,203 shares of Common Stock (the “Warrants”).”
FibroBiologics, Inc. issued 8,570,203 pre-funded warrants of warrant to a single investor for sovereign-issued .9999 fine gold coins valued at $4,069.18 per oz. based on the spot price of gold at the time of signing of the Purchase Agreement.
“below. The exercise price of the Warrants is $0.3303 per share. The purchase price for the Shares or Pre-Funded Warrants will be paid not in cash but with sovereign-issued .9999 fine gold coins valued at $4,069.18 per oz. based on the spot price of gold at the time of signing of the Purchase Agreement, delivered to the Company’s depository. The Company”
FibroBiologics, Inc. issued 3,540,000 shares of common stock to a single investor for sovereign-issued .9999 fine gold coins valued at $4,069.18 per oz. based on the spot price of gold at the time of signing of the Purchase Agreement.
“below. The exercise price of the Warrants is $0.3303 per share. The purchase price for the Shares or Pre-Funded Warrants will be paid not in cash but with sovereign-issued .9999 fine gold coins valued at $4,069.18 per oz. based on the spot price of gold at the time of signing of the Purchase Agreement, delivered to the Company’s depository. The Company”
FibroBiologics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).
“August 4, 2025, FibroBiologics, Inc. (the “Company”) received a notification letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it does not meet the requirement in Nasdaq Listing Rule 5550(b)(2) to maintain a minimum Market Value of Listed Securities (“MVLS”) of $35.0 million that is required for continued listing on The Nasdaq Capital Market (the “Notice”). The Notice has no immediate impact on the listing of the Company’s common stock, which will continue to be listed and traded on The Nasdaq Capital Market subject”
FibroBiologics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“July 1, 2025, FibroBiologics, Inc. (the “Company”) received a notification letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the closing bid price of the Company’s shares of common stock was below the minimum closing bid price of $1.00 per share during the last 30 consecutive trading days (the “Notice”), as required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The Notice has no immediate impact on the listing of the Company’s common stock, which will continue to be listed a”
FibroBiologics, Inc. incurred convertible notes of $5 million with YA II PN, Ltd. at 0% maturing December 20, 2025.
“The third tranche of the Pre-Paid Advance was disbursed on June 16, 2025 (the “Third Closing”) in the principal amount of $5 million and evidenced by a convertible promissory note (the “Third Promissory Note).”
FibroBiologics, Inc.: The company filed an amendment to its Amended and Restated Certificate of Incorporation, effective June 12, 2025, to increase its authorized capital stock (effective 2025-06-12).
“On June 12, 2025, FibroBiologics, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized capital stock (the “Amendment”), which became effective the same day.”
Jason D. Davis was appointed as Chief Financial Officer at FibroBiologics, Inc..
“On June 9, 2025, FibroBiologics, Inc. (the “Company”) announced that Jason D. Davis has been appointed as the Company’s Chief Financial Officer, effective as of June 9, 2025 (the “Effective Date”).”
Robert E. Hoffman resigned as Interim Chief Financial Officer at FibroBiologics, Inc..
“On May 2, 2025, Mr. Robert E. Hoffman informed FibroBiologics, Inc. (the “Company”) of his decision to voluntarily resign from his position as the Company’s Interim Chief Financial Officer, effective as of the close of business on May 14, 2025.”
Mark Andersen resigned as Chief Financial Officer at FibroBiologics, Inc..
“On October 25, 2024, Mr. Mark Andersen informed FibroBiologics, Inc. (the “Company”) of his decision to voluntarily resign from his position as the Company’s Chief Financial Officer”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.